Skip to main content
PMC home page
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2011 Jul 12;1:13. doi: 10.3389/fonc.2011.00013

Sequence Variants and the Risk of Head and Neck Cancer: Pooled Analysis in the INHANCE Consortium

Shu-Chun Chuang 1,2, Antonio Agudo 3, Wolfgang Ahrens 4, Devasena Anantharaman 5, Simone Benhamou 6, Stefania Boccia 7,8, Chu Chen 9, David I Conway 10, Eleonora Fabianova 11, Richard B Hayes 12, Claire M Healy 13, Ivana Holcatova 14, Kristina Kjaerheim 15, Pagona Lagiou 16, Philip Lazarus 17, Tatiana V Macfarlane 18, Manoj B Mahimkar 5, Dana Mates 19, Keitaro Matsuo 20, Franco Merletti 21, Andres Metspalu 22, Hal Morgenstern 23,24, Joshua Muscat 17, Gabriella Cadoni 25, Andrew F Olshan 26, Mark Purdue 27, Heribert Ramroth 28, Peter Rudnai 29, Stephen M Schwartz 9, Lorenzo Simonato 30, Elaine M Smith 31, Erich M Sturgis 32, Neonilia Szeszenia-Dabrowska 33, Renato Talamini 34, Peter Thomson 35, Qingyi Wei 32, David Zaridze 36, Zuo-Feng Zhang 37, Ariana Znaor 38, Paul Brennan 1, Paolo Boffetta 1,39,40, Mia Hashibe 1,41,*
PMCID: PMC3356135  PMID: 22655231

Abstract

Previous molecular epidemiological studies on head and neck cancer have examined various single nucleotide polymorphisms (SNPs), but there are very few documented associations. In the International head and neck cancer epidemiology (INHANCE) consortium, we evaluated associations between SNPs in the metabolism, cell cycle, and DNA repair pathways and the risk of head and neck cancer. We analyzed individual-level pooled data from 14 European, North American, Central American, and Asia case–control studies (5,915 head and neck cancer cases and 10,644 controls) participating in the INHANCE consortium. Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for SNP effects, adjusting for age, sex, race, and country. We observed an association between head and neck cancer risk and MGMT Leu84Phe heterozygotes (OR = 0.79, 95% CI = 0.68–0.93), XRCC1 Arg194Trp homozygotes Arg/Arg (OR = 2.3, 95% CI = 1.1–4.7), ADH1B Arg48His homozygotes Arg/Arg (OR = 2.7, 95% CI = 1.9–4.0), ADH1C Ile350Val homozygotes Ile/Ile (OR = 1.2, 95% CI = 1.1–1.4), and the GSTM1 null genotype (OR = 1.1, 95% CI = 1.0–1.2). Among these results, MGMT Leu84Phe, ADH1B Arg48His, ADH1C Ile350Arg, and the GSTM1 null genotype had fairly low false positive report probabilities (<20%). We observed associations between ADH1B Arg48His, ADH1C Ile350Arg, and GSTM1 null genotype and head and neck cancer risk. No functional study currently supports the observed association for MGMT Leu84Phe, and the association with XRCC1 Arg194Trp may be a chance finding.

Keywords: SNP, head and neck cancer, INHANCE

Introduction

Head and neck cancer, including cancers in oral cavity, pharynx (other than nasopharynx), and larynx, is the sixth most common cancer in the world (Parkin et al., 2005). It accounted for about 900,000 of cases and 300,000 deaths in 2008 (Ferlay et al., 2010). The 5-year survival rate was about 61% in the US for all sites (Altekruse et al., 2010) and 26 to 63% in Europe depending on the subsite (Berrino et al., 2007). The major risk factors for head and neck cancer are tobacco smoking and alcohol drinking (Hashibe et al., 2007). The interaction between tobacco smoking and alcohol drinking is greater than the expected multiplicative null with an overall attributable risk of 72% (Hashibe et al., 2009). Other risk factors include human papillomavirus (HPV) infection (IARC Working Group/Human Papillomaviruses, 2007), passive smoking (Lee et al., 2008), low body mass index (BMI; Gaudet et al., 2010), poor diet (World Cancer Research Fund/American Institute for Cancer Research, 2007), and family history of cancer (Negri et al., 2009).

Previous molecular epidemiological studies on head and neck cancer have examined single nucleotide polymorphisms (SNPs), focusing on metabolic and DNA repair genes (Sturgis and Wei, 2002; Hashibe et al., 2003, 2008; Canova et al., 2009); however, very few SNP associations have been consistent for head and neck cancer risk. The heterogeneity may result from study design, e.g., population- or hospital-based controls, study sample size, and study populations, e.g., race/ethnicity (Hashibe et al., 2003; Lohmueller et al., 2003). The International head and neck cancer epidemiology (INHANCE) consortium is a collaboration of research groups leading large molecular epidemiology studies of head and neck cancer. Since larger sample sizes can increase the precision of the effect measure estimates and the ability to detect statistically significant moderate associations, we pooled data on SNPs that were genotyped in common across the INHANCE studies, to evaluate the associations between the SNPs in several pathways and the risk of head and neck cancer.

Materials and Methods

The INHANCE consortium (http://inhance.iarc.fr/) was established in 2004. Fourteen studies participating in the consortium contributed SNP data: France (Benhamou et al., 2004), Central Europe (Hashibe et al., 2006), Seattle (Schwartz et al., 2001; Huang et al., 2005), Iowa (Wang et al., 2005), North Carolina (Olshan et al., 2000), Los Angeles (Cui et al., 2006), Houston (Zhang et al., 2005), Puerto Rico (Hayes et al., 1999), Rome (Boccia et al., 2008), Western Europe (Canova et al., 2009), Heidelberg (Risch et al., 2003), Japan (Suzuki et al., 2007), Northeast US (Park et al., 2003), and India (Anantharaman et al., 2007). Descriptions of the individual studies are presented in the Table A1 in Appendix. To increase power, we included all controls selected for lung and kidney cancers in the Central Europe multicenter case–control study, in addition to the head and neck cancer controls. There were 6,694 head and neck cancer cases and 12,601 controls.

Cases and controls with missing data on age, sex, race/ethnicity, or SNP information, and cases with missing information on the site of origin of their cancer were excluded (779 cases and 1,957 controls). In total, 5,915 cases and 10,644 controls were included in the analysis. Among the cases, 1,901 were oral cancer, 1,751 were pharyngeal cancer, 440 were cancers of the oral cavity or pharynx not otherwise specified, 1,632 were laryngeal cancer and 191 overlapping or subsite missing.

Written informed consent was obtained from all study subjects and the investigations were approved by institutional review boards at each of the institutes involved. Questionnaires were collected from all the individual studies, to assess the comparability of the collected data and of the wording of interview questions among the studies. Each data item was checked for illogical or missing values and inconsistencies were resolved as necessary.

Details on harmonizing questionnaire data have been published previously (Hashibe et al., 2007). Briefly, the definitions for ever smoking and drinking are different across studies. We reclassified ever tobacco smokers as those who have smoked at least 100 cigarettes or 100 cigars or 100 pipes in their lifetime. In our previous analyses, drinking (≥3 alcoholic drinks/day) was associated increased HNC risks (Hashibe et al., 2007), we thus classified heavy drinkers as those who have consumed three or more alcoholic drinks per day.

Single nucleotide polymorphisms reported in more than two studies were included in the current pooled analyses. In total, 28 SNPs in cell cycle (p21 Ser31Arg rs1801270 and p53 Pro72Arg rs1042522), DNA repair (ERCC2 Lys751Gln rs28365048, MGMT Leu84Phe rs12917, Ile143Val rs2308321, 171C > T rs1803965, OGG1 Ser326Cys rs1052133, XRCC1 Arg194Trp rs1799782, Arg280His rs25489, Arg399Gln rs25487, and XRCC3 Thr241Met rs861539), folate metabolism (MTHFR Ala222Val rs1801133 and Glu429Ala rs1801131), and carcinogen metabolism (ADH1B Arg48His rs1229984, ADH1C Ile350Val rs698, CYP1A1 Ile462Val rs1048943, 3801T > C E0322, CYP2E1 1054C > T rs2031920, 1143A > T rs6413432, 1293G > C rs3813867, EPHX1 Try113His rs1051740, His139Arg rs2234922, GSTM1 null, GSTM3 Mnl AGG deletion rs1799735, GSTP1 Ile105Val rs947894, Ala114Val rs1799811, GSTT1 null, NQO1 Pro187Ser rs1800566) pathways were included. Hardy–Weinberg equilibrium was tested in the controls by study. SNPs which did not pass the test in a specific study were excluded from the analyses.

The associations between SNPs and head and neck cancer risk were assessed by estimating odds ratios (OR) and 95% confidence intervals (CI) with unconditional logistic regression models for each study. The models included age (categories), sex, race/ethnicity (categories), and country (categories). In the Central Europe study, information on ethnicity was not collected and all subjects were classified as non-Hispanic white, since the majority of these populations were expected to be white. Pooled ORs were estimated with a fixed effects and random effects (DerSimonian and Laird, 1986) logistic regression model. We assessed heterogeneity across studies by the likelihood ratio test. Stratified analyses were conducted by cancer site (oral, pharynx, oral/pharynx not specified, and larynx), age (<45 and ≥45 years), sex, race (White, Black, Hispanic, and Asian) geographic region (Europe, North America, and Latin America), study type (hospital-based and population-based), study size (<300 cases and ≥300 cases), smoking (never and ever), drinking [≤3 and >3 drinks/day (Hashibe et al., 2007)] and fruit and vegetable intake (lower and higher than center-specific median among controls). The analyses were performed using SAS 9 and significant associations were defined as a two-sided p-value less than 0.05.

False positive report probability (FPRP; Wacholder et al., 2004) was assessed for all associations in which the two-sided null p-value was less than 0.05. FPRP was assessed for OR = 1.5 for probability of true association were 0.25, 0.1, 0.01, and 0.001. For the haplotype analysis, we selected the studies that had information on the multiple SNPs for the gene. We used PHASE v2. (Stephens et al., 2001; Stephens and Donnelly, 2003) to reconstruct the haplotype for genes with multiple SNPs available. Overall, haplotypes for four genes, CYP2E1, EPHX1, GSTP1, and MTHFR, could be reconstructed. The most frequent haplotype was treated as the referent group.

Results

A total of 5,915 cases and 10,644 controls were pooled from 14 studies in Europe (2,759 cases and 4,629 controls), North America (2,234 cases and 3,290 controls), Central America (147 cases and 149 controls), and Asia (775 cases and 2,576 controls). Demographic characteristics of the cases and controls are presented in Table 1. Among the cell cycle and DNA repair SNPs, we observed associations between head and neck cancer risk and MGMT Leu84Phe heterozygotes (OR = 0.79, 95% CI = 0.68–0.93) and XRCC1 Arg194Trp rare homozygotes (OR = 2.3, 95% CI = 1.1–4.7; Table 2).

Table 1.

Demographic characteristics of head and neck cancer cases and controls.

Cases
 Controls
n % n %
All 5915 10644
SEX
Female 1251 21.1 2765 26.0
Male 4664 78.9 7879 74.0
AGE
≤44 655 11.1 1545 14.5
45–49 628 10.6 1117 10.5
50–59 2014 34.0 3333 31.3
60–69 1664 28.1 2991 28.1
70+ 954 16.1 1658 15.6
RACE
White 4676 79.1 7298 68.6
Black 267 4.5 383 3.6
Hispanic 117 2.0 273 2.6
Asian 811 13.7 2647 24.9
Others 44 0.7 43 0.4
STUDY COUNTRY
France France 256 4.3 173 1.6
Central Europe Romania 103 1.7 185 1.7
Poland 189 3.2 814 7.6
Russia 303 5.1 805 7.6
Slovakia 40 0.7 196 1.8
Seattle USA 360 6.1 560 5.3
Iowa USA 366 6.2 330 3.1
North Carolina USA 174 2.9 196 1.8
Los Angeles USA 320 5.4 915 8.6
Houston USA 828 14.0 865 8.1
Puerto Rico Puerto Rico 147 2.5 149 1.4
Rome Italy 277 4.7 293 2.8
Western Europe Czech Republic 111 1.9 152 1.4
Germany 175 3.0 179 1.7
Greece 190 3.2 160 1.5
Italy 378 6.4 446 4.2
Ireland 17 0.3 16 0.2
Norway 110 1.9 137 1.3
UK 236 4.0 301 2.8
Spain 76 1.3 81 0.8
Croatia 52 0.9 46 0.4
Heidelberg Germany 246 4.2 645 6.1
Japan Japan 320 5.4 1848 17.4
Northeast US USA 186 3.1 424 4.0
India India 455 7.7 728 6.8
Open in a new tab

Table 2.

Cell cycle and DNA repair SNPs and the risk of head and neck cancer in the INHANCE consortium.

Gene SNP rs number Alteration Referent genotype No. Of cases No. Of controls Analysis model Heterozygotes
 Rare homozygotes
OR (95%CI) No. of studies p for heterogeneity OR (95%CI) No. of studies p for heterogeneity
P21 rs1801270 Ser31Arg Ser/Ser 2301 3920 Fixed effects 1.11 (0.94–1.30) 3 0.01 1.41 (0.75–2.64) 3 0.09
Random effects 1.24 (0.55–2.77) 1.52 (0.27–8.66)
P53 rs1042522 Pro72Arg Arg/Arg 2982 4488 Fixed effects 0.97 (0.87–1.07) 4 0.52 0.97 (0.80–1.17) 4 0.07
Random effects 0.97 (0.82–1.14) 0.97 (0.71–1.32)
ERCC2 rs28365048 Lys751Gln Lys/Lys 2587 4771 Fixed effects 0.97 (0.86–1.09) 5 0.75 1.03 (0.88–1.21) 5 0.48
Random effects 0.97 (0.82–1.14) 1.03 (0.83–1.29)
MGMT rs1803965 171C > T C/C 2310 3936 Fixed effects 0.98 (0.86–1.11) 3 0.61 1.05 (0.74–1.50) 3 0.21
Random effects 0.98 (0.73–1.30) 1.06 (0.47–2.38)
MGMT rs2308321 Ile143Val Ile/Ile 2684 4349 Fixed effects 0.90 (0.79–1.02) 6 0.18 1.20 (0.81–1.79) 6 0.68
Random effects 0.90 (0.76–1.06) 1.20 (0.71–2.02)
MGMT rs12917 Leu84Phe Leu/Leu 1455 3160 Fixed effects 0.79 (0.68–0.93) 5 0.79 1.40 (0.94–2.07) 5 0.69
Random effects 0.79 (0.64–0.99) 1.40 (0.80–2.44)
OGG1 rs1052133 Ser326Cys Ser/Ser 1680 4825 Fixed effects 0.95 (0.83–1.08) 5 0.89 0.98 (0.77–1.24) 5 0.67
Random effects 0.95 (0.79–1.14) 0.98 (0.69–1.38)
XRCC1 rs1799782 Arg194Trp Arg/Arg 1272 2984 Fixed effects 1.02 (0.83–1.26) 4 0.76 2.30 (1.13–4.67) 4 1.00
Random effects 1.02 (0.72–1.44) 2.30 (0.73–7.26)
XRCC1 rs25489 Arg280His Arg/Arg 903 2794 Fixed effects 1.12 (0.88–1.44) 2 0.84 2.87 (0.95–8.67) 2 0.21
Random effects 1.12 (0.23–5.58) 2.87 (0.00–3719)
XRCC1 rs25487 Arg399Gln Arg/Arg 2602 4255 Fixed effects 0.93 (0.83–1.03) 6 0.21 1.00 (0.84–1.19) 6 0.01
Random effects 0.93 (0.80–1.07) 0.89 (0.58–1.37)
XRCC3 rs861539 Thr241Met Thr/Thr 2707 4544 Fixed effects 0.96 (0.86–1.07) 7 0.14 0.90 (0.77–1.06) 7 0.88
Random effects 0.96 (0.84–1.10) 0.90 (0.74–1.10)
Open in a new tab

OR adjusted for age, sex, country, and race.

For the carcinogen metabolism SNPs, associations were observed between head and neck cancer risk and ADH1B Arg48His His/His homozygotes (OR = 2.7, 95% CI = 1.9–4.0), ADH1C Ile350Val rare homozygotes (OR = 1.2, 95% CI = 1.1–1.4), and the GSTM1 null type (OR = 1.1, 95% CI = 1.0–1.2; Table 3). Further adjusting for cigarette smoking and alcohol consumption (Table A2 in Appendix) did not change the results greatly. In addition, XRCC1 Arg280His rare homozygotes showed an association with head and neck cancer risk after adjustment of cigarette smoking and alcohol consumption (OR = 3.3, 95% CI = 1.1–10).

Table 3.

Carcinogen metabolism SNPs and the risk of head and neck cancer in the INHANCE consortium.

Gene SNP rs number Alteration Referent genotype No. Of cases No. Of controls Analysis model Heterozygotes
 Rare homozygotes
OR (95%CI) No. of studies p for heterogeneity OR (95%CI) No. of studies p for heterogeneity
MTHFR rs1801131 Glu429Ala Glu/Glu 830 2164 Fixed effects 0.90 (0.75–1.07) 2 0.14 0.95 (0.69–1.31) 2 0.25
Random effects 0.90 (0.29–2.82) 0.95 (0.12–7.66)
MTHFR rs1801133 Ala222Val Ala/Ala 2605 5444 Fixed effects 0.98 (0.88–1.09) 5 0.87 1.04 (0.88–1.23) 4 0.69
Random effects 0.98 (0.85–1.14) 1.04 (0.80–1.36)
ADH1B rs1229984 Arg48His His/His 2407 5408 Fixed effects 1.15 (0.92–1.43) 4 0.95 2.73 (1.87–3.98) 3 0.94
Random effects 1.15 (0.80–1.65) 2.73 (1.19–6.26)
ADH1C rs698 Ile350Val Ile/Ile 3306 6264 Fixed effects 1.06 (0.96–1.18) 9 0.42 1.22 (1.06–1.41) 9 0.09
Random effects 1.06 (0.93–1.21) 1.19 (0.94–1.50)
CYP1A1 E0322 3801T > C T/T 1062 2657 Fixed effects 0.95 (0.80-–1.14) 2 0.24 1.41 (0.94–2.12) 2 0.36
Random effects 0.95 (0.30–2.98) 1.41 (0.10–19.9)
CYP1A1 rs1048943 Ile462Val Ile/Ile 2814 4823 Fixed effects 0.96 (0.81–1.14) 7 0.56 0.70 (0.35–1.43) 4 1.00
Random effects 0.96 (0.77–1.19) 0.70 (0.22–2.23)
CYP2E1 rs6413432 1143A > T A/A 722 974 Fixed effects 1.20 (0.85–1.69) 2 0.13 1.39 (0.41–4.74) 2 0.60
Random effects 1.21 (0.12–11.9) 1.39 (0.00–3889)
CYP2E1 rs3813867 1293G > C G/G 1789 3797 Fixed effects 0.86 (0.66–1.13) 5 0.72 1.65 (0.10–26.7) 4 1.00
Random effects 0.86 (0.59–1.26) 1.65 (0.02–151.9)
CYP2E1 rs2031920 1054C > T C/C 981 1414 Fixed effects 1.18 (0.80-–1.74) 4 0.66 1.66 (0.10–26.9) 4 1.00
Random effects 1.18 (0.63–2.22) 1.66 (0.02–152.7)
EPHX1 rs2234922 His139Arg His/His 2840 4464 Fixed effects 0.94 (0.84–1.05) 6 0.25 1.24 (0.97–1.58) 6 0.25
Random effects 0.94 (0.81–1.08) 1.24 (0.89–1.71)
EPHX1 rs1051740 Tyr113His Tyr/Tyr 2882 4923 Fixed effects 1.01 (0.91–1.11) 6 <0.01 0.89 (0.75–1.05) 6 0.86
Random effects 0.94 (0.71–1.26) 0.89 (0.71–1.11)
GSTM1 NA Null present 3857 7232 Fixed effects NA 1.11 (1.02–1.20) 12 0.33
Random effects NA 1.11 (1.00–1.23)
GSTM3 rs1799735 MnlI AGG > del AGG/AGG 1039 2478 Fixed effects 1.02 (0.85–1.22) 3 0.38 0.90 (0.60–1.36) 3 0.72
Random effects 1.02 (0.69–1.51) 0.90 (0.37–2.23)
GSTP1 rs1799811 Ala114Val Ala/Ala 2447 2757 Fixed effects 1.00 (0.85–1.18) 4 0.46 1.35 (0.77–2.35) 4 0.27
Random effects 1.00 (0.76–1.31) 1.35 (0.55–3.32)
GSTP1 rs947894 Ile105Val Ile/Ile 4086 6461 Fixed effects 1.01 (0.93–1.11) 9 0.23 1.01 (0.88–1.16) 9 0.61
Random effects 1.01 (0.91–1.13) 1.01 (0.85–1.18)
GSTT1 NA Null present 3704 6919 Fixed effects NA 0.91 (0.81–1.01) 11 0.13
Random effects NA 0.91 (0.78–1.05)
NQO1 rs1800566 Pro187Ser Pro/Pro 1896 4038 Fixed effects 1.03 (0.91–1.17) 5 0.73 1.19 (0.88–1.61) 5 0.07
Random effects 1.03 (0.86–1.23) 1.21 (0.68–2.16)
Open in a new tab

OR adjusted for age, sex, country, and race.

Table 4 shows the FPRP for the observed associations for the selected SNPS under a given range of probability of true associations. If the prior probability is greater than 10% and we assume the expected OR = 1.5, the FPRPs for MGMT Leu84Phe, ADH1B Arg48His, ADH1C Ile350Val, and GSTM1 were lower than 20%.

Table 4.

False positive report probabilities (FPRP) for observed associations for selected SNPs.

SNPs Ca Co OR FPRP for OR = 1.5 and for different probabilities of a true association
0.250 0.100 0.010 0.001
MGMT L84F Leu/Phe 307 823 0.79 0.014 0.041 0.319 0.825
Phe/Phe 43 81 1.40 0.302 0.565 0.935 0.993
XRCC1 R194W Arg/Trp 155 359 1.02 0.719 0.885 0.988 0.999
Trp/Trp 16 21 2.30 0.349 0.617 0.947 0.994
ADH1B R48H Arg/His 467 1194 1.15 0.387 0.655 0.954 0.995
His/His 1710 3018 2.73 0.001 0.002 0.019 0.161
ADH1C I350V Ile/Val 1383 2252 1.06 0.463 0.721 0.966 0.997
Val/Val 579 778 1.22 0.021 0.060 0.413 0.877
GSTM1 null 1906 3386 1.11 0.025 0.073 0.463 0.897
Open in a new tab

OR adjusted for age, sex, country, race.

Odds ratios for selected SNPs by head and neck cancer subsite are shown in Table 5. ADH1B His48Arg and ADH1C Ile350Val were consistently associated with oral, pharyngeal, and oral/pharyngeal NOS cancer, but ADH1C Ile350Val was not associated with laryngeal cancer. The association of GSTM1 null genotype was observed only with oral cancer (OR = 1.2 95% CI = 1.0–1.3).

Table 5.

Selected SNPs and the risk of head and neck cancer by subsite.

Oral OR (95% CI) Pharynx OR (95% CI) Oral/pharynx. NOS OR (95% CI) Larynx OR (95% CI)
ADH1B His48Arg (ca/co) 541/5157 593/5157 208/5157 981/5408
His/His 1.00 1.00 1.00 1.00
His/Arg 1.46 (0.86–2.47) 0.98 (0.61–1.27) 1.06 (0.68–1.64) 0.87 (0.56–1.34)
Arg/Arg 2.37 (1.31–4.30) 5.71 (3.22–10.1) 2.27 (1.14–4.52) 1.50 (0.67–3.38)
Ptrend <0.01 <0.01 0.03 0.08
His/Arg or Arg/Arg 1.89 (1.29–2.78) 2.80 (2.00–3.92) 2.22 (1.34–3.69) 1.55 (1.16–2.07)
ADH1C I350V (ca/co) 980/6013 1097/6013 240/6013 940/5255
Ile/Ile 1.00 1.00 1.00 1.00
Ile/Val 1.18 (0.99–1.40) 1.10 (0.93–1.30) 1.16 (0.80–1.67) 0.90 (0.75–1.08)
Val/Val 1.40 (1.12–1.76) 1.22 (0.98–1.52) 2.08 (1.19–3.63) 1.11 (0.88–1.41)
Ptrend 0.01 <0.01 0.22 <0.01
Ile/Val or Val/Val 1.22 (1.04–1.44) 1.13 (0.97–1.32) 1.24 (0.87–1.76) 0.94 (0.80–1.12)
GSTM1 (ca/co) 1236/6637 1068/5911 260/5911 798/3620
Present 1.00 1.00 1.00 1.00
Null 1.15 (1.01–1.32) 0.95 (0.83–1.10) 1.06 (0.82–1.38) 1.06 (0.89–1.26)
Open in a new tab

OR adjusted for age, sex, country, and race.

Figure 1 shows the stratified results for the selected SNPs, comparing the rare homozygotes to the common homozygotes. The effects from ADH1B Arg48His tended to be stronger among ever smokers and heavy drinkers than non-smokers and light drinkers. The associations from ADH1C Ile350Val were much stronger among Hispanic and Asian; however, these were based on relatively small numbers (case/control in the rare homozygotes: 16/10 for Hispanic and 2/3 for Asian).

Figure 1.

Figure 1

Open in a new tab

Stratified analysis for selected SNPs: (A) ADH1B Arg48His; His/His vs. Arg/Arg (B) ADH1C Ile350Val: Val/Val vs. Ile/Ile; (C) GSTM1 null genotype.

Table 6 further evaluated the joint effects among smoking, drinking, and the selected SNPs. There was no evidence for the interaction between drinking and ADH1B Arg48His and ADH1C Ile350Val, and smoking and GSTM1 on the risk of head and neck cancer.

Table 6.

Joint effects of drinking and ADH1B Arg48His and ADH1C Ile350Val and smoking and GSTM1 on the risk of head and neck cancer.

Lifestyle SNP Case Control OR 95% CI
Drinking* ADH1B Arg48His
Light His/His or His/Arg 331 1773 1.00
Light Arg/Arg 949 2186 1.73 (0.96–3.14)
Heavy His/His or His/Arg 292 503 1.96 (1.12–3.43)
Heavy Arg/Arg 711 552 4.03 (0.95–17.0)
Interaction 1.21 (0.43–3.41)
Drinking* ADH1C Ile350Val
Light Ile/Ile or Ile/Val 1458 4004 1.00
Light Val/Val 327 566 1.18 (0.88–1.59)
Heavy Ile/Ile or Ile/Val 906 893 2.45 (1.79–3.37)
Heavy Val/Val 197 117 2.42 (1.64–3.56)
Interaction 0.97 (0.62–1.52)
Smoking GSTM1
No Present 398 1414 1.00
No Null 385 1246 1.16 (0.94–1.42)
Yes Present 1328 1865 3.03 (1.78–5.17)
Yes Null 1318 1761 3.11 (1.92–5.06)
Interaction 0.86 (0.66–1.12)
Open in a new tab

*Heavy drinkers were defined as those who drank > 40 ml/day.

No obvious associations were observed for the haplotypes of CYP2E1, EPHX1, GSTP1, and MTHFR (data not shown).

Discussion

Our results showed associations between head and neck cancer risk and genetic variants in MGMT Leu84Phe, XRCC1 Arg194Trp, ADH1B Arg48His, ADH1C Ile350Val, and the GSTM1. Among them, the results for XRCC1 Arg194Trp might be a false finding because the FPRP was high even if the prior probability was set to be high (0.25).

Among the four studies reported XRCC1 Arg194Trp, none of them were statistically significant with a total of 16 cases and 21 controls in the Trp/Trp group (Table 4). In the International lung cancer consortium, which pooled five studies with 26 cases and 28 controls in the rare homozygote group, reported a non-statistically significant association with increased lung cancer risk (Hung et al., 2008). In a meta-analysis on DNA damage response genes and head and neck cancer reported an increased oral cancer risk for XRCC1 194Trp in the Asian population; however, no association was observed in the Caucasian population (Flores-Obando et al., 2010). A meta-analysis investigated the associations between DNA repair gene polymorphisms and smoking and found that XRCC1 194Trp, 280His, and 399Gln were associated with smoking behaviors (Hodgson et al., 2010). Nevertheless, further adjusted for smoking and drinking behaviors did not change the results materially, even though the association with 280His becomes statistically significant (Table A2 in Appendix). Further investigation into the XRCC1 function and its association in tobacco induced gene repair might be helpful to elucidate the associations with head and neck cancer risks.

Association between MGMT Leu84Phe and head and neck cancer risk was observed in the present report. The effects were similar regarding the cigarette smoking and alcohol drinking status, age, sex, and race (data not shown). The FPRP was 0.787 if the priority probability was very low (0.001). However, the associations between heterozygotes and rare homozygotes and head and neck cancer risk were in different directions. The results for the rare homozygotes were imprecise across the five studies provided the SNP (OR = 1.60, 0.90, 0.80, 1.55, and 0.66). Excluding the largest study which provided 608 cases and 1925 controls (OR = 1.60) in the analyses yield an OR 0f 0.99 (0.33–3.02). Nevertheless, the function of the MGMT Leu84Phe rare allele is not thought to differ from that of common homozygotes (based on the purified protein in the repair of O6-methylguanine in vitro; Pegg et al., 2007). In addition, more than 500 SNPs have been identified in MGMT in Caucasians and ∼60% of the identified SNPs have minor allele frequency greater than 0.05 (Bugni et al., 2007). The MGMT polymorphism might be associated with MGMT hypermethylation (Ogino et al., 2007), which could cause mutations in other critical genes (Mukai and Sekiguchi, 2002). The observed association might be a result of the mutated gene or an unidentified causal SNP. More studies would be needed to explore the associations and the mechanisms between MGMT polymorphisms and head and neck cancer.

Both ADH1B and ADH1C gene belongs to the ADH class I family, which plays a major role in ethanol metabolism (Edenberg, 2000). ADH1C 350Val and 272Arg result in a faster metabolism of ethanol (Hoog et al., 1986; Carr et al., 1989). Earlier associations on ADH1B and head and neck cancer were based on Asian studies (Hori et al., 1997; Yokoyama et al., 1999, 2001; Asakage et al., 2007; Hiraki et al., 2007). Recently, two large case–control studies further confirmed the association in European populations (Hashibe et al., 2006, 2008). The current analysis included the above studies; however, none of the study is influential on the overall pooled estimates. The differences in the published results could be because the frequency of the His allele is extremely low in the European population (International HapMap Project, 2008). In our study, only 1.2% European subjects carried the His/His genotype while 61.3% Asian participants had the polymorphism. Despite the differences in distribution, the effects from the SNP did not differ by populations (Figure 1). The effects from ADH1B Arg/Arg were stronger among ever smokers or heavy drinkers. People who carry the ADH1B Arg/Arg genotype also tended to consume more alcohol than those who carried the His/His or His/Arg genotype (Table A3 in Appendix).

Earlier studies found no association between ADH1C Ile350Val and head and neck cancers (Coutelle et al., 1997; Bouchardy et al., 2000; Olshan et al., 2001; Sturgis et al., 2001; Wang et al., 2005) while some recent studies reported associations as main effects or combined effects with alcohol drinking (Harty et al., 1997; Peters et al., 2005; Hashibe et al., 2006). A large study (Hashibe et al., 2008) combining data from Europe and Latin America further suggested associations of ADH1B, ADH1C, and ADH7 genes with head and neck cancer risk. In the present pooled analysis, which combined data from Europe, North America, Latin America, and Asia, we observed an overall 25% increased risk of head and neck cancer on ADH1C Ile350Val, especially among oral and pharyngeal cancer patients. The result from Asia was very unstable possibly due to the low frequency of the homozygotes in the population. Excluding the Asian study from the analysis did not change the results materially.

ADH1B Arg48His and ADH1C Ile350Val genes are only 100 kb away and have strong linkage disequilibrium (LD > 0.65; International HapMap Project, 2008). However, after restriction to the ADH1B His/His or His/Arg population, ADH1C Val/Val still showed strong association on head and neck cancer risk. The frequency was very low in the European population and thus the statistical power was low (data not shown).

GSTM1 belongs to the glutathione S-transferases (GST) family producing phase II xenobiotic metabolic enzymes. The GSTs play a role in the metabolism of chemical carcinogens, especially with regard to those present in tobacco smoke (Peters et al., 2006). However, epidemiological studies on the associations between GSTs and head and neck cancer have been inconsistent. The inconsistency could be attributed to study design, for example, population-based controls vs. hospital-based controls, matching criteria, and incident cases vs. prevalent cases (Geisler and Olshan, 2001). The GST enzymes are also known to be expressed differently by site (Pacifici et al., 1988; Moscow et al., 1989; Howie et al., 1990). In the present study, GSTM1 null genotype was associated with oral cavity cancer but not the other head and neck cancer sites.

Interestingly, race seems to be a potential effect modifier for the association between GSTM1 and head and neck cancer, with ORs of 1.1 for Whites, Blacks, and Hispanic and 1.3 for Asians, even though the CI overlapped. The OR for Asians in North America was 1.3 (case/control: 28/64, 95% CI = 0.11–16).

In addition, significant results were only observed in the hospital-based studies for the association between GSTM1 and head and neck cancer. Hospital-based studies in our study exclude individuals with previous or malignant disease, including respiratory disease (France, Rome, North Carolina, Northeast US, India), tobacco or alcohol related diseases (Central Europe and Western Europe) or from hospital visitors (Houston). The GSTM1 genotype distribution among the hospital-based controls may not reflect those of the base population in our study. Among controls, the hospital-based studies had lower frequency of the null type GSTM1 than population-based studies (45 vs. 52%, p < 0.0001).

A limitation of our study is that the pooled analysis is based on a heterogeneous population from different geographic regions and ethnicities. However, heterogeneity across studies was not significant for most of our results. In addition, stratified analysis was conducted to assess whether our observations were due to a specific geography and ethnicity. In addition, individual data was available and were harmonized according to standard protocol; thus, we were able to control the potential confounders consistently.

A genome-wide association study (GWAS) was performed independently within the INHANCE consortium using HumanHap300 platform (McKay et al., 2011). The GWAS used the Central Europe and Western Europe studies for the discovery phase and replicated the findings in another subset of the INHANCE consortium: Los Angeles, Houston, Latin America, IARC Multicenter, Boston, and Rome studies, in combination with additional studies not in the current pooled analyses. The ADH1C Ile350Val was strongly associated with the head and neck cancer in the discovery phase (p < 10−5) and was replicated in the replication phase. The ADH1B His48Arg was not tagged on HumanHap300 but was selected as a candidate gene for the replication and showed the strongest association in the replication phase (p = 3 × 10−12). Inconsistency has been observed between results from candidate gene approach and from GWAS in previous studies (Siontis et al., 2010). The consistent findings in the two ADH SNPs in both GWAS (McKay et al., 2011) and a previous analyses (Hashibe et al., 2006) as well as the current pooled analyses based on candidate gene approach further support the role of alcohol metabolism genes on the head and neck cancer etiology. Our observations suggest that, while GWAS may lead to novel hypotheses by elucidating new disease associated loci, traditional hypotheses-driven associations should not be ignored.

In summary, we observed associations between ADH1B Arg48His, ADH1C Ile350Arg, GSTM1 null and head and neck cancer risk. An association for XRCC1 Arg194Trp was not well supported based on the FPRPs. Further investigation is needed for MGMT Leu84Phe for the mechanism. ADH1B Arg48His and ADH1C Ile350Arg could be risk factors or markers of other risk genes for head and neck cancer. Effect of GSTM1 is slightly associated with increased risk of head and neck cancer but inconsistent across subsites.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

This pooled analysis of SNPs within INHANCE consortium was supported by a grant from the US National Institutes of Health (NIH), National Institute of Dental, and Craniofacial Research (NIDCR; R03DE016611). Shu-Chun Chuang worked on this project during the tenure of a Special Training Award from the International Agency for Research on Cancer. The individual studies were funded by the following grants: France study: Swiss League against Cancer (KFS1069-09-2000), Fribourg League against Cancer (FOR381.88), Swiss Cancer Research (AKT 617), and Gustave-Roussy Institute (88D28). Central Europe study: World Cancer Research Fund and the European Commission's INCO-COPERNICUS Program (Contract No. IC15-CT98-0332). Seattle study: National Institutes of Health (NIH) US (R01CA048996, R01DE012609). Iowa: National Institutes of Health (NIH) US (NIDCR R01DE11979, NIDCR R01DE13110, NIH FIRCA TW01500) and Veterans Affairs Merit Review Funds. North Carolina study: National Institutes of Health (NIH) US (R01CA61188), and in part by a grant from the National Institute of Environmental Health Sciences (P30ES010126). Los Angeles study: National Institute of Health (NIH) US (P50CA90388, R01DA11386, R03CA77954, T32CA09142, U01CA96134, R21ES011667) and the Alper Research Program for Environmental Genomics of the UCLA Jonsson Comprehensive Cancer Center. Houston: National Institutes of Health (NIH) US (R01ES11740, R01CA100264). Puerto Rico study: jointly funded by National Institutes of Health (NCI) US and NIDCR intramural programs. Rome study: AIRC (Italian Agency for Research on Cancer). Western Europe Study: European Commission's 5th Framework Program (Contract No. QLK1-2001-00182), Italian Association for Cancer Research, Compagnia di San Paolo/FIRMS, Region Piemonte, and Padova University (Contract No. CPDA057222). Germany-Heidelberg study: grant No. 01GB9702/3 from the German Ministry of Education and Research. Japan study: Scientific Research grant from the Ministry of Education, Science, Sports, Culture, and Technology of Japan (17015052) and grant for the Third-Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labor, and Welfare of Japan (H20-002). Northeast US: National Institutes of Health (NIH) US (R01DE13158). India: Department of Biotechnology Government of India (DBT Grant no: BT/PR2277/MED/09/333/2000 and BT/PR6958/MED/14/912/2005).

Appendix

Table A1.

Summary of individual studies involved in the current analysis.

Study location (reference†) Recruitment period Platform/method¥ Case subjects
 Control subjects‡
Source Participation rate, % Age eligibility years Source Participation rate, %
Europe
Paris, France (Benhamou et al., 2004) 1987–1992 PCR-RFLP Hospital 95§ NA Hospital (unhealthy) 95§
Central Europe (Banska Bystrica, Bucharest, Budapest, Lodz, Moscow)|| (Hashibe et al., 2006) 1998–2003 TaqMan Hospital 96 ≥15 Hospital (unhealthy) 97
Rome (Boccia et al., 2008) 2002–2007 PCR-RFLP Hospital 98 NA Hospital (unhealthy) 94
Western Europe (Canova et al., 2009) 2000–2005 APEX Hospital 82 Hospital (unhealthy)* 68
Heidelberg, Germany (Risch et al., 2003) 1998–2000 PCR-RFLP Hospital 96 <80 Population registry 62
North America
Seattle, WA Crump et al. (2000), Huang et al. (2005), Schwartz et al. (2001) 1985–1995 PCR-RFLP, multiplex, or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry Cancer registry 54.4, 63.3 18–65 Random digit dialing 63, 61
Iowa (Wang et al., 2005) 1993–2006 PCR-RFLP Hospital 87 >17 Hospital (healthy) 92
North Carolina (Olshan et al., 2000) 1994–1997 Multiplex Hospital 88 >17 Hospital (unhealthy) 86
Los Angeles, CA (Cui et al., 2006) 1999–2004 PCR-RFLP Cancer registry 49 18–65 Neighborhood 67.5
Houston, TX (Zhang et al., 2005) 2001–2006 PCR-RFLP Hospital 95 ≥18 Hospital visitors >80
Northeast, US (Park et al., 2003) 1994–2000 PCR-RFLP Hospital NA Hospital (unhealthy)
Latin America
Puerto Rico (Hayes et al., 1999) 1992–1995 PCR-RFLP or TaqMan Cancer registry 71 21–79 Residential records 83
Asia
India (Anantharaman et al., 2007) 2001–2004 PCR-RFLP Hospital NA Hospital (unhealthy)
Japan (Suzuki et al., 2007) 2001–2005 TaqMan Hospital 61 20–79 Hospital (unhealthy) 41
Open in a new tab

NA = not applicable/not available.

†Representative publication in which study methods are described.

‡All studies frequency matched control subjects to case subjects on age and sex. Additional frequency matching factors included study center (Central Europe), hospital (France study), ethnicity (Northeast US), neighborhood (Los Angeles study), and tobacco and alcohol habits (India).

§Participation rate was not formally assessed, estimated response rate reported.

||Multicenter study.

Two response rates are reported because data were collected in two population-based case–control studies, the first from 1985 to 1989 among men and the second from 1990 to 1995 among men and women.

*The three UK centers (Glasgow, Manchester, and Newcastle) from the Western European study were chosen from the same family medical practice (population-based).

Table A2.

Single nucleotide polymorphisms and the risk of head and neck cancer, adjusted for smoking and drinking (exclude Northeast US study).

Gene SNP rs number Alteration Referent genotype Analysis model Heterozygotes
 Rare homozygotes
OR (95%CI) No. of studies p for heterogeneity OR (95%CI) No. of studies p for heterogeneity
P21 rs1801270 Ser31Arg Ser/Ser Fixed effects 1.14 (0.96–1.36) 3 0.01 1.59 (0.81–3.12) 3 0.14
Random effects 1.24 (0.60–2.56) 1.62 (0.32–8.19)
P53 rs1042522 Pro72Arg Arg/Arg Fixed effects 0.96 (0.86–1.08) 4 0.48 0.96 (0.78–1.18) 4 0.28
Random effects 0.96 (0.80–1.15) 0.96 (0.69–1.35)
ERCC2 rs28365048 Lys751Gln Lys/Lys Fixed effects 0.95 (0.84–1.09) 5 0.53 1.06 (0.89–1.25) 5 0.63
Random effects 0.95 (0.79–1.15) 1.06 (0.83–1.35)
MGMT rs1803965 171C> T C/C Fixed effects 0.97 (0.84–1.11) 3 0.58 1.03 (0.70–1.53) 3 0.08
Random effects 0.97 (0.71–1.32) 1.08 (0.33–3.58)
MGMT rs2308321 Ile143Val Ile/Ile Fixed effects 0.90 (0.78–1.03) 6 0.52 1.32 (0.85–2.04) 6 0.66
Random effects 0.90 (0.75–1.07) 1.32 (0.75–2.34)
MGMT rs12917 Leu84Phe Leu/Leu Fixed effects 0.80 (0.68–0.95) 5 0.66 1.49 (0.96–2.30) 5 0.83
Random effects 0.80 (0.63–1.02) 1.49 (0.80–2.76)
OGG1 rs1052133 Ser326Cys Ser/Ser Fixed effects 0.95 (0.82–1.09) 5 0.95 1.00 (0.77–1.30) 5 0.62
Random effects 0.95 (0.78–1.16) 1.00 (0.70–1.45)
XRCC1 rs1799782 Arg194Trp Arg/Arg Fixed effects 0.94 (0.74–1.18) 4 0.89 2.31 (1.04–5.11) 4 0.98
Random effects 0.94 (0.64–1.37) 2.31 (0.64–8.40)
XRCC1 rs25489 Arg280His Arg/Arg Fixed effects 1.09 (0.84–1.43) 2 0.87 3.28 (1.06–10.2) 2 0.20
Random effects 1.09 (0.19–6.24) 3.28 (0.00–5008)
XRCC1 rs25487 Arg399Gln Arg/Arg Fixed effects 0.94 (0.83–1.06) 6 0.48 0.99 (0.82–1.21) 6 0.02
Random effects 0.94 (0.80–1.10) 0.97 (0.72–1.30)
XRCC3 rs861539 Thr241Met Thr/Thr Fixed effects 0.98 (0.87–1.10) 7 0.06 0.97 (0.81–1.16) 7 0.70
Random effects 0.98 (0.84–1.14) 0.97 (0.78–1.21)
MTHFR rs1801131 Glu429Ala Glu/Glu Fixed effects 0.87 (0.71–1.05) 2 0.21 0.83 (0.59–1.19) 2 0.29
Random effects 0.87 (0.25–3.00) 0.83 (0.08–8.31)
MTHFR rs1801133 Ala222Val Ala/Ala Fixed effects 1.03 (0.92–1.16) 5 0.92 1.04 (0.87–1.25) 4 0.33
Random effects 1.03 (0.88–1.22) 1.04 (0.78–1.40)
ADH1B rs1229984 Arg48His Arg/Arg Fixed effects 1.04 (0.82–1.32) 4 0.95 2.35 (1.57–3.53) 3 0.93
Random effects 1.04 (0.71–1.53) 2.35 (0.97–5.74)
ADH1C rs1042758 Ile350Val Ile/Ile Fixed effects 1.01 (0.90–1.14) 9 0.68 1.20 (1.03–1.40) 9 0.22
Random effects 1.01 (0.89–1.16) 1.17 (0.93–1.46)
CYP1A1 E0322 3801T > C T/T Fixed effects 0.97 (0.80–1.18) 2 0.87 1.52 (0.94–2.47) 2 0.28
Random effects 0.97 (0.27–3.53) 1.52 (0.07–34.9)
CYP1A1 rs1048943 Ile462Val Ile/Ile Fixed effects 0.97 (0.80–1.18) 7 0.72 0.84 (0.39–1.79) 4 0.99
Random effects 0.97 (0.76–1.24) 0.84 (0.25–2.86)
CYP2E1 rs6413432 1143A > T A/A Fixed effects 1.32 (0.89–1.96) 2 0.06 1.25 (0.30–5.22) 2 0.97
Random effects 1.38 (0.05–40.2) 1.25 (0.00–13439)
CYP2E1 rs3813867 1293G > C G/G Fixed effects 0.74 (0.53–1.04) 4 0.88 4.44 (0.27–72.7) 3 1.00
Random effects 0.74 (0.43–1.27) 4.44 (0.01–2051)
CYP2E1 rs2031920 1054C > T C/C Fixed effects 1.15 (0.68–1.95) 3 0.25 4.45 (0.27–72.7) 3 1.00
Random effects 1.15 (0.36–3.66) 4.45 (0.01–2052)
EPHX1 rs2234922 His139Arg His/His Fixed effects 0.92 (0.82–1.04) 6 0.82 1.31 (1.00–1.72) 6 0.24
Random effects 0.92 (0.79–1.08) 1.31 (0.92–1.87)
EPHX1 rs1051740 Tyr113His Tyr/Tyr Fixed effects 0.98 (0.88–1.10) 6 0.01 0.86 (0.71–1.04) 6 0.56
Random effects 0.92 (0.70–1.22) 0.86 (0.67–1.10)
GSTM1 NA null present Fixed effects NA 1.08 (0.98–1.19) 11 0.45
Random effects NA 1.08 (0.96–1.22)
GSTM3 rs1799735 MnlI AGG > del AGG/AGG Fixed effects 1.03 (0.83–1.27) 2 0.15 0.81 (0.43–1.50) 2 0.44
Random effects 1.03 (0.25–4.16) 0.81 (0.01–46.1)
GSTP1 rs1799811 Ala114Val Ala/Ala Fixed effects 1.04 (0.87–1.25) 3 0.60 1.21 (0.65–2.24) 3 0.18
Random effects 1.04 (0.69–1.56) 1.20 (0.27–5.38)
GSTP1 rs947894 Ile105Val Ile/Ile Fixed effects 1.02 (0.92–1.12) 8 0.35 0.95 (0.81–1.11) 8 0.40
Random effects 1.02 (0.90–1.14) 0.95 (0.79–1.15)
GSTT1 NA null present Fixed effects NA 0.92 (0.82–1.04) 11 0.13
Random effects NA 0.92 (0.80–1.06)
NQO1 rs1800566 Pro187Ser Pro/Pro Fixed effects 1.02 (0.89–1.17) 5 0.68 1.07 (0.77–1.49) 5 0.01
Random effects 1.02 (0.84–1.24) 1.11 (0.52–2.37)
Open in a new tab

OR adjusted for age, sex, country, race, pack years of smoking, and alcohol drinking. Data from Northeast US were excluded because of missing in alcohol drinking.

Table A3.

Mean and median of alcohol drinking (ml/day) by ADH1B Are48His genotype.

Study Allele Mean Median p
Central Europe His/His or His/Arg 25.28 13.17 0.42
Arg/Arg 25.01 11.36
Western Europe His/His or His/Arg 21.12 9.47 0.01
Arg/Arg 27.04 15.92
Heidelberg His/His or His/Arg 45.96 27.69
Arg/Arg NA NA
Japan His/His or His/Arg 23.58 7.92 <0.01
Arg/Arg 28.71 23.76
Open in a new tab

p-value was determined by Wilcoxon rank sum test.

References

  1. International HapMap Project (2008). International HapMap Project. Available at http://hapmap.ncbi.nlm.nih.gov/
  2. Altekruse S. F., Kosary C. L., Krapcho M., Neyman N., Aminou R., Waldron W., Ruhl J., Howlader N., Tatalovich Z., Cho H., Mariotto A., Eisner M. P., Lewis D. R., Cronin K., Chen H. S., Feuer E. J., Stinchcomb D. G., Edwards B. K. (eds). (2010). SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute; Available at: http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010 [Google Scholar]
  3. Anantharaman D., Chaubal P. M., Kannan S., Bhisey R. A., Mahimkar M. B. (2007). Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians: tobacco exposure as a risk modulator. Carcinogenesis 7, 1455–1462 10.1093/carcin/bgm038 [DOI] [PubMed] [Google Scholar]
  4. Asakage T., Yokoyama A., Haneda T., Yamazaki M., Muto M., Yokoyama T., Kato H., Igaki H., Tsujinaka T., Kumagai Y., Yokoyama M., Omori T., Watanabe H. (2007). Genetic polymorphisms of alcohol and aldehyde dehydrogenases, and drinking, smoking and diet in Japanese men with oral and pharyngeal squamous cell carcinoma. Carcinogenesis 4, 865–874 [DOI] [PubMed] [Google Scholar]
  5. Benhamou S., Tuimala J., Bouchardy C., Dayer P., Sarasin A., Hirvonen A. (2004). DNA repair gene XRCC2 and XRCC3 polymorphisms and susceptibility to cancers of the upper aerodigestive tract. Int. J. Cancer 5, 901–904 10.1002/ijc.20474 [DOI] [PubMed] [Google Scholar]
  6. Berrino F., De Angelis R., Sant M., Rosso S., Bielska-Lasota M., Coebergh J. W., Santaquilani M. (2007). Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol. 9, 773–783 10.1016/S1470-2045(07)70245-0 [DOI] [PubMed] [Google Scholar]
  7. Boccia S., Cadoni G., Sayed-Tabatabaei F. A., Volante M., Arzani D., De Lauretis A., Cattel C., Almadori G., van Duijn C. M., Paludetti G., Ricciardi G. (2008). CYP1A1, CYP2E1, GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2 polymorphisms, smoking, consumption of alcohol and fruit and vegetables and risk of head and neck cancer. J. Cancer Res. Clin. Oncol. 1, 93–100 [DOI] [PubMed] [Google Scholar]
  8. Bouchardy C., Hirvonen A., Coutelle C., Ward P. J., Dayer P., Benhamou S. (2000). Role of alcohol dehydrogenase 3 and cytochrome P-4502E1 genotypes in susceptibility to cancers of the upper aerodigestive tract. Int. J. Cancer 5, 734–740 [DOI] [PubMed] [Google Scholar]
  9. Bugni J. M., Han J., Tsai M. S., Hunter D. J., Samson L. D. (2007). Genetic association and functional studies of major polymorphic variants of MGMT. DNA Repair (Amst.) 8, 1116–1126 10.1016/j.dnarep.2007.03.023 [DOI] [PubMed] [Google Scholar]
  10. Canova C., Hashibe M., Simonato L., Nelis M., Metspalu A., Lagiou P., Trichopoulos D., Ahrens W., Pigeot I., Merletti F., Richiardi L., Talamini R., Barzan L., Macfarlane G. J., Macfarlane T. V., Holcatova I., Bencko V., Benhamou S., Bouchardy C., Kjaerheim K., Lowry R., Agudo A., Castellsague X., Conway D. I., McKinney P. A., Znaor A., McCartan B. E., Healy C. M., Marron M., Brennan P. (2009). Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. Cancer Res. 7, 2956–2965 10.1158/0008-5472.CAN-08-2604 [DOI] [PubMed] [Google Scholar]
  11. Carr L. G., Xu Y., Ho W. H., Edenberg H. J. (1989). Nucleotide sequence of the ADH2(3) gene encoding the human alcohol dehydrogenase beta 3 subunit. Alcohol. Clin. Exp. Res. 4, 594–596 10.1111/j.1530-0277.1989.tb00383.x [DOI] [PubMed] [Google Scholar]
  12. Coutelle C., Ward P. J., Fleury B., Quattrocchi P., Chambrin H., Iron A., Couzigou P., Cassaigne A. (1997). Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. Hum. Genet. 3, 319–325 10.1007/s004390050365 [DOI] [PubMed] [Google Scholar]
  13. Crump C., Chen C., Appelbaum F. R., Kopecky K. J., Schwartz S. M., Willman C. L., Slovak M. L., Weiss N. S. (2000). Glutathione S-transferase theta 1 gene deletion and risk of acute myeloid leukemia. Cancer Epidemiol. Biomarkers Prev. 5, 457–460 [PubMed] [Google Scholar]
  14. Cui Y., Morgenstern H., Greenland S., Tashkin D. P., Mao J., Cao W., Cozen W., Mack T. M., Zhang Z. F. (2006). Polymorphism of Xeroderma pigmentosum group G and the risk of lung cancer and squamous cell carcinomas of the oropharynx, larynx and esophagus. Int. J. Cancer 3, 714–720 10.1002/ijc.21413 [DOI] [PubMed] [Google Scholar]
  15. DerSimonian R., Laird N. (1986). Meta-analysis in clinical trials. Control. Clin. Trials 3, 177–188 10.1016/0197-2456(86)90046-2 [DOI] [PubMed] [Google Scholar]
  16. Edenberg H. J. (2000). Regulation of the mammalian alcohol dehydrogenase genes. Prog. Nucleic Acid Res. Mol. Biol. 295–341 10.1016/S0079-6603(00)64008-4 [DOI] [PubMed] [Google Scholar]
  17. Ferlay J., Shin H. R., Bray F., Forman D., Mathers C., Parkin D. M. (2010). GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10, International Agency for Research on Cancer, Lyon: Available at: http://globocan.iarc.fr [Google Scholar]
  18. Flores-Obando R. E., Gollin S. M., Ragin C. C. (2010). Polymorphisms in DNA damage response genes and head and neck cancer risk. Biomarkers 5, 379–399 10.3109/13547501003797664 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gaudet M. M., Olshan A. F., Chuang S. C., Berthiller J., Zhang Z. F., Lissowska J., Zaridze D., Winn D. M., Wei Q., Talamini R., Szeszenia-Dabrowska N., Sturgis E. M., Schwartz S. M., Rudnai P., Eluf-Neto J., Muscat J., Morgenstern H., Menezes A., Matos E., Bucur A., Levi F., Lazarus P., La V. C., Koifman S., Kelsey K., Herrero R., Hayes R. B., Franceschi S., Wunsch-Filho V., Fernandez L., Fabianova E., Daudt A. W., Dal M. L., Curado M. P., Chen C., Castellsague X., Benhamou S., Boffetta P., Brennan P., Hashibe M. (2010). Body mass index and risk of head and neck cancer in a pooled analysis of case-control studies in the International head and neck cancer epidemiology (INHANCE) consortium. Int. J. Epidemiol. 4, 1091–1102 10.1093/ije/dyp380 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Geisler S. A., Olshan A. F. (2001). GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: a mini-HuGE review. Am. J. Epidemiol. 2, 95–105 10.1093/aje/154.2.95 [DOI] [PubMed] [Google Scholar]
  21. Harty L. C., Caporaso N. E., Hayes R. B., Winn D. M., Bravo-Otero E., Blot W. J., Kleinman D. V., Brown L. M., Armenian H. K., Fraumeni J. F., Jr., Shields P. G. (1997). Alcohol dehydrogenase 3 genotype and risk of oral cavity and pharyngeal cancers. J. Natl. Cancer Inst. 22, 1698–1705 [DOI] [PubMed] [Google Scholar]
  22. Hashibe M., Boffetta P., Zaridze D., Shangina O., Szeszenia-Dabrowska N., Mates D., Janout V., Fabianova E., Bencko V., Moullan N., Chabrier A., Hung R., Hall J., Canzian F., Brennan P. (2006). Evidence for an important role of alcohol- and aldehyde-metabolizing genes in cancers of the upper aerodigestive tract. Cancer Epidemiol. Biomarkers Prev. 4, 696–703 10.1158/1055-9965.EPI-05-0710 [DOI] [PubMed] [Google Scholar]
  23. Hashibe M., Brennan P., Benhamou S., Castellsague X., Chen C., Curado M. P., Dal Maso L., Daudt A. W., Fabianova E., Fernandez L., Wunsch-Filho V., Franceschi S., Hayes R. B., Herrero R., Koifman S., La Vecchia C., Lazarus P., Levi F., Mates D., Matos E., Menezes A., Muscat J., Eluf-Neto J., Olshan A. F., Rudnai P., Schwartz S. M., Smith E., Sturgis E. M., Szeszenia-Dabrowska N., Talamini R., Wei Q., Winn D. M., Zaridze D., Zatonski W., Zhang Z. F., Berthiller J., Boffetta P. (2007). Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International head and neck cancer epidemiology consortium. J. Natl. Cancer Inst. 10, 777–789 [DOI] [PubMed] [Google Scholar]
  24. Hashibe M., Brennan P., Chuang S. C., Boccia S., Castellsague X., Chen C., Curado M. P., Dal M. L., Daudt A. W., Fabianova E., Fernandez L., Wunsch-Filho V., Franceschi S., Hayes R. B., Herrero R., Kelsey K., Koifman S., La V. C., Lazarus P., Levi F., Lence J. J., Mates D., Matos E., Menezes A., McClean M. D., Muscat J., Eluf-Neto J., Olshan A. F., Purdue M., Rudnai P., Schwartz S. M., Smith E., Sturgis E. M., Szeszenia-Dabrowska N., Talamini R., Wei Q., Winn D. M., Shangina O., Pilarska A., Zhang Z. F., Ferro G., Berthiller J., Boffetta P. (2009). Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International head and neck cancer epidemiology consortium. Cancer Epidemiol. Biomarkers Prev. 2, 541–550 10.1158/1055-9965.EPI-08-0347 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Hashibe M., Brennan P., Strange R. C., Bhisey R., Cascorbi I., Lazarus P., Oude Ophuis M. B., Benhamou S., Foulkes W. D., Katoh T., Coutelle C., Romkes M., Gaspari L., Taioli E., Boffetta P. (2003). Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. Cancer Epidemiol. Biomarkers Prev. 12, 1509–1517 [PubMed] [Google Scholar]
  26. Hashibe M., McKay J. D., Curado M. P., Oliveira J. C., Koifman S., Koifman R., Zaridze D., Shangina O., Wunsch-Filho V., Eluf-Neto J., Levi J. E., Matos E., Lagiou P., Lagiou A., Benhamou S., Bouchardy C., Szeszenia-Dabrowska N., Menezes A., Dall'Agnol M. M., Merletti F., Richiardi L., Fernandez L., Lence J., Talamini R., Barzan L., Mates D., Mates I. N., Kjaerheim K., Macfarlane G. J., Macfarlane T. V., Simonato L., Canova C., Holcatova I., Agudo A., Castellsague X., Lowry R., Janout V., Kollarova H., Conway D. I., McKinney P. A., Znaor A., Fabianova E., Bencko V., Lissowska J., Chabrier A., Hung R. J., Gaborieau V., Boffetta P., Brennan P. (2008). Multiple ADH genes are associated with upper aerodigestive cancers. Nat. Genet. 6, 707–709 10.1038/ng.151 [DOI] [PubMed] [Google Scholar]
  27. Hayes R. B., Bravo-Otero E., Kleinman D. V., Brown L. M., Fraumeni J. F., Jr., Harty L. C., Winn D. M. (1999). Tobacco and alcohol use and oral cancer in Puerto Rico. Cancer Causes Control 1, 27–33 10.1023/A:1008876115797 [DOI] [PubMed] [Google Scholar]
  28. Hiraki A., Matsuo K., Wakai K., Suzuki T., Hasegawa Y., Tajima K. (2007). Gene-gene and gene-environment interactions between alcohol drinking habit and polymorphisms in alcohol-metabolizing enzyme genes and the risk of head and neck cancer in Japan. Cancer Sci. 7, 1087–1091 10.1111/j.1349-7006.2007.00505.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hodgson M. E., Poole C., Olshan A. F., North K. E., Zeng D., Millikan R. C. (2010). Smoking and selected DNA repair gene polymorphisms in controls: systematic review and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 12, 3055–3086 10.1158/1055-9965.EPI-10-0877 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Hoog J. O., Heden L. O., Larsson K., Jornvall H., Bahr-Lindstrom H. (1986). The gamma 1 and gamma 2 subunits of human liver alcohol dehydrogenase. cDNA structures, two amino acid replacements, and compatibility with changes in the enzymatic properties. Eur. J. Biochem. 2, 215–218 10.1111/j.1432-1033.1986.tb09855.x [DOI] [PubMed] [Google Scholar]
  31. Hori H., Kawano T., Endo M., Yuasa Y. (1997). Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and human esophageal squamous cell carcinoma susceptibility. J. Clin. Gastroenterol. 4, 568–575 10.1097/00004836-199712000-00003 [DOI] [PubMed] [Google Scholar]
  32. Howie A. F., Forrester L. M., Glancey M. J., Schlager J. J., Powis G., Beckett G. J., Hayes J. D., Wolf C. R. (1990). Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues. Carcinogenesis 3, 451–458 10.1093/carcin/11.3.451 [DOI] [PubMed] [Google Scholar]
  33. Huang W. Y., Olshan A. F., Schwartz S. M., Berndt S. I., Chen C., Llaca V., Chanock S. J., Fraumeni J. F., Jr., Hayes R. B. (2005). Selected genetic polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and risk of head and neck cancer: a pooled analysis. Cancer Epidemiol. Biomarkers Prev. 7, 1747–1753 10.1158/1055-9965.EPI-05-0162 [DOI] [PubMed] [Google Scholar]
  34. Hung R. J., Christiani D. C., Risch A., Popanda O., Haugen A., Zienolddiny S., Benhamou S., Bouchardy C., Lan Q., Spitz M. R., Wichmann H. E., LeMarchand L., Vineis P., Matullo G., Kiyohara C., Zhang Z. F., Pezeshki B., Harris C., Mechanic L., Seow A., Ng D. P., Szeszenia-Dabrowska N., Zaridze D., Lissowska J., Rudnai P., Fabianova E., Mates D., Foretova L., Janout V., Bencko V., Caporaso N., Chen C., Duell E. J., Goodman G., Field J. K., Houlston R. S., Hong Y. C., Landi M. T., Lazarus P., Muscat J., McLaughlin J., Schwartz A. G., Shen H., Stucker I., Tajima K., Matsuo K., Thun M., Yang P., Wiencke J., Andrew A. S., Monnier S., Boffetta P., Brennan P. (2008). International lung cancer consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways. Cancer Epidemiol. Biomarkers Prev. 11, 3081–3089 10.1158/1055-9965.EPI-08-0411 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. IARC Working Group/Human Papillomaviruses. (2007). IARC Monograph on the Evaluation of Carcinogenic Risks to Humans, Vol. 90 Lyon: IRAC Press, 1–1438 [PMC free article] [PubMed] [Google Scholar]
  36. Lee Y. C., Boffetta P., Sturgis E. M., Wei Q., Zhang Z. F., Muscat J., Lazarus P., Matos E., Hayes R. B., Winn D. M., Zaridze D., Wunsch-Filho V., Eluf-Neto J., Koifman S., Mates D., Curado M. P., Menezes A., Fernandez L., Daudt A. W., Szeszenia-Dabrowska N., Fabianova E., Rudnai P., Ferro G., Berthiller J., Brennan P., Hashibe M. (2008). Involuntary smoking and head and neck cancer risk: pooled analysis in the International head and neck cancer epidemiology consortium. Cancer Epidemiol. Biomarkers Prev. 8, 1974–1981 10.1158/1055-9965.EPI-08-0047 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Lohmueller K. E., Pearce C. L., Pike M., Lander E. S., Hirschhorn J. N. (2003). Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat. Genet. 2, 177–182 10.1038/ng1071 [DOI] [PubMed] [Google Scholar]
  38. McKay J. D., Truong T., Gaborieau V., Chabrier A., Chuang S. C., Byrnes G., Zaridze D., Shangina O., Szeszenia-Dabrowska N., Lissowska J., Rudnai P., Fabianova E., Bucur A., Bencko V., Holcatova I., Janout V., Foretova L., Lagiou P., Trichopoulos D., Benhamou S., Bouchardy C., Ahrens W., Merletti F., Richiardi L., Talamini R., Barzan L., Kjaerheim K., Macfarlane G. J., Macfarlane T. V., Simonato L., Canova C., Agudo A., Castellsague X., Lowry R., Conway D. I., McKinney P. A., Healy C. M., Toner M. E., Znaor A., Curado M. P., Koifman S., Menezes A., Wunsch-Filho V., Neto J. E., Garrote L. F., Boccia S., Cadoni G., Arzani D., Olshan A. F., Weissler M. C., Funkhouser W. K., Luo J., Lubinski J., Trubicka J., Lener M., Oszutowska D., Schwartz S. M., Chen C., Fish S., Doody D. R., Muscat J. E., Lazarus P., Gallagher C. J., Chang S. C., Zhang Z. F., Wei Q., Sturgis E. M., Wang L. E., Franceschi S., Herrero R., Kelsey K. T., McClean M. D., Marsit C. J., Nelson H. H., Romkes M., Buch S., Nukui T., Zhong S., Lacko M., Manni J. J., Peters W. H., Hung R. J., McLaughlin J., Vatten L., Njolstad I., Goodman G. E., Field J. K., Liloglou T., Vineis P., Clavel-Chapelon F., Palli D., Tumino R., Krogh V., Panico S., Gonzalez C. A., Quiros J. R., Martinez C., Navarro C., Ardanaz E., Larranaga N., Khaw K. T., Key T., Bueno-de-Mesquita H. B., Peeters P. H., Trichopoulou A., Linseisen J., Boeing H., Hallmans G., Overvad K., Tjonneland A., Kumle M., Riboli E., Valk K., Voodern T., Metspalu A., Zelenika D., Boland A., Delepine M., Foglio M., Lechner D., Blanche H., Gut I. G., Galan P., Heath S., Hashibe M., Hayes R. B., Boffetta P., Lathrop M., Brennan P. (2011). A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium. PLoS Genet. 3, e1001333. 10.1371/journal.pgen.1001333 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Moscow J. A., Fairchild C. R., Madden M. J., Ransom D. T., Wieand H. S., O'Brien E. E., Poplack D. G., Cossman J., Myers C. E., Cowan K. H. (1989). Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res. 6, 1422–1428 [PubMed] [Google Scholar]
  40. Mukai T., Sekiguchi M. (2002). Gene silencing in phenomena related to DNA repair. Oncogene 58, 9033–9042 10.1038/sj.onc.1206095 [DOI] [PubMed] [Google Scholar]
  41. Negri E., Boffetta P., Berthiller J., Castellsague X., Curado M. P., Dal Maso L., Daudt A. W., Fabianova E., Fernandez L., Wunsch-Filho V., Franceschi S., Hayes R. B., Herrero R., Koifman S., Lazarus P., Lence J. J., Levi F., Mates D., Matos E., Menezes A., Muscat J., Eluf-Neto J., Olshan A. F., Rudnai P., Shangina O., Sturgis E. M., Szeszenia-Dabrowska N., Talamini R., Wei Q., Winn D. M., Zaridze D., Lissowska J., Zhang Z. F., Ferro G., Brennan P., La Vecchia C., Hashibe M. (2009). Family history of cancer: pooled analysis in the International head and neck cancer epidemiology consortium. Int. J. Cancer 2, 394–401 10.1002/ijc.23848 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Ogino S., Hazra A., Tranah G. J., Kirkner G. J., Kawasaki T., Nosho K., Ohnishi M., Suemoto Y., Meyerhardt J. A., Hunter D. J., Fuchs C. S. (2007). MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis 9, 1985–1990 10.1093/carcin/bgm160 [DOI] [PubMed] [Google Scholar]
  43. Olshan A. F., Weissler M. C., Watson M. A., Bell D. A. (2000). GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol. Biomarkers Prev. 2, 185–191 [PubMed] [Google Scholar]
  44. Olshan A. F., Weissler M. C., Watson M. A., Bell D. A. (2001). Risk of head and neck cancer and the alcohol dehydrogenase 3 genotype. Carcinogenesis 1, 57–61 10.1093/carcin/22.1.57 [DOI] [PubMed] [Google Scholar]
  45. Pacifici G. M., Franchi M., Bencini C., Repetti F., Di Lascio N., Muraro G. B. (1988). Tissue distribution of drug-metabolizing enzymes in humans. Xenobiotica 7, 849–856 10.3109/00498258809041723 [DOI] [PubMed] [Google Scholar]
  46. Park J. Y., Schantz S. P., Lazarus P. (2003). Epoxide hydrolase genotype and orolaryngeal cancer risk: interaction with GSTM1 genotype. Oral Oncol. 5, 483–490 10.1016/S1368-8375(03)00008-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Parkin D. M., Bray F., Ferlay J., Pisani P. (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 2, 74–108 10.3322/canjclin.55.2.74 [DOI] [PubMed] [Google Scholar]
  48. Pegg A. E., Fang Q., Loktionova N. A. (2007). Human variants of O6-alkylguanine-DNA alkyltransferase. DNA Repair (Amst.) 8, 1071–1078 10.1016/j.dnarep.2007.03.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Peters E. S., McClean M. D., Liu M., Eisen E. A., Mueller N., Kelsey K. T. (2005). The ADH1C polymorphism modifies the risk of squamous cell carcinoma of the head and neck associated with alcohol and tobacco use. Cancer Epidemiol. Biomarkers Prev. 2, 476–482 10.1158/1055-9965.EPI-04-0431 [DOI] [PubMed] [Google Scholar]
  50. Peters E. S., McClean M. D., Marsit C. J., Luckett B., Kelsey K. T. (2006). Glutathione S-transferase polymorphisms and the synergy of alcohol and tobacco in oral, pharyngeal, and laryngeal carcinoma. Cancer Epidemiol. Biomarkers Prev. 11, 2196–2202 10.1158/1055-9965.EPI-06-0503 [DOI] [PubMed] [Google Scholar]
  51. Risch A., Ramroth H., Raedts V., Rajaee-Behbahani N., Schmezer P., Bartsch H., Becher H., Dietz A. (2003). Laryngeal cancer risk in Caucasians is associated with alcohol and tobacco consumption but not modified by genetic polymorphisms in class I alcohol dehydrogenases ADH1B and ADH1C, and glutathione-S-transferases GSTM1 and GSTT1. Pharmacogenetics 4, 225–230 10.1097/00008571-200304000-00007 [DOI] [PubMed] [Google Scholar]
  52. Schwartz S. M., Doody D. R., Fitzgibbons E. D., Ricks S., Porter P. L., Chen C. (2001). Oral squamous cell cancer risk in relation to alcohol consumption and alcohol dehydrogenase-3 genotypes. Cancer Epidemiol. Biomarkers Prev. 11, 1137–1144 [PubMed] [Google Scholar]
  53. Siontis K. C., Patsopoulos N. A., Ioannidis J. P. (2010). Replication of past candidate loci for common diseases and phenotypes in 100 genome-wide association studies. Eur. J. Hum. Genet. 7, 832–837 10.1038/ejhg.2010.26 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Stephens M., Donnelly P. (2003). A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 5, 1162–1169 10.1086/379378 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Stephens M., Smith N. J., Donnelly P. (2001). A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 4, 978–989 10.1086/319501 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Sturgis E. M., Dahlstrom K. R., Guan Y., Eicher S. A., Strom S. S., Spitz M. R., Wei Q. (2001). Alcohol dehydrogenase 3 genotype is not associated with risk of squamous cell carcinoma of the oral cavity and pharynx. Cancer Epidemiol. Biomarkers Prev. 3, 273–275 [PubMed] [Google Scholar]
  57. Sturgis E. M., Wei Q. (2002). Genetic susceptibility–molecular epidemiology of head and neck cancer. Curr. Opin. Oncol. 3, 310–317 10.1097/00001622-200205000-00010 [DOI] [PubMed] [Google Scholar]
  58. Suzuki T., Matsuo K., Hasegawa Y., Hiraki A., Wakai K., Hirose K., Saito T., Sato S., Ueda R., Tajima K. (2007). One-carbon metabolism-related gene polymorphisms and risk of head and neck squamous cell carcinoma: case-control study. Cancer Sci. 9, 1439–1446 10.1111/j.1349-7006.2007.00533.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Wacholder S., Chanock S., Garcia-Closas M., El Ghormli L., Rothman N. (2004). Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J. Natl. Cancer Inst. 6, 434–442 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Wang D., Ritchie J. M., Smith E. M., Zhang Z., Turek L. P., Haugen T. H. (2005). Alcohol dehydrogenase 3 and risk of squamous cell carcinomas of the head and neck. Cancer Epidemiol. Biomarkers Prev. 3, 626–632 10.1158/1055-9965.EPI-04-0343 [DOI] [PubMed] [Google Scholar]
  61. World Cancer Research Fund/American Institute for Cancer Research. (2007). Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective, AICR, Washington, DC [Google Scholar]
  62. Yokoyama A., Muramatsu T., Omori T., Matsushita S., Yoshimizu H., Higuchi S., Yokoyama T., Maruyama K., Ishii H. (1999). Alcohol and aldehyde dehydrogenase gene polymorphisms influence susceptibility to esophageal cancer in Japanese alcoholics. Alcohol. Clin. Exp. Res. 11, 1705–1710 10.1111/j.1530-0277.1999.tb04064.x [DOI] [PubMed] [Google Scholar]
  63. Yokoyama A., Muramatsu T., Omori T., Yokoyama T., Matsushita S., Higuchi S., Maruyama K., Ishii H. (2001). Alcohol and aldehyde dehydrogenase gene polymorphisms and oropharyngolaryngeal, esophageal and stomach cancers in Japanese alcoholics. Carcinogenesis 3, 433–439 10.1093/carcin/22.3.433 [DOI] [PubMed] [Google Scholar]
  64. Zhang Z., Shi Q., Liu Z., Sturgis E. M., Spitz M. R., Wei Q. (2005). Polymorphisms of methionine synthase and methionine synthase reductase and risk of squamous cell carcinoma of the head and neck: a case-control analysis. Cancer Epidemiol. Biomarkers Prev. 5, 1188–1193 10.1158/1055-9965.EPI-04-0501 [DOI] [PubMed] [Google Scholar]

Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES